Ratings by TD Cowen (Steven Mah)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/4/2025 | Twist Bioscience | TWST | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2025 | Twist Bioscience | TWST | Maintain | Buy (N/A) |
|
Details | ||
| 11/26/2024 | Twist Bioscience | TWST | Maintain | Buy (N/A) |
|
Details | ||
| 11/18/2024 | Twist Bioscience | TWST | Maintain | Buy (N/A) |
|
Details | ||
| 9/20/2024 | Ginkgo Bioworks Holdings Inc | DNA | Maintain | Buy (N/A) |
|
Details | ||
| 9/17/2024 | Ginkgo Bioworks Holdings Inc | DNA | Maintain | Buy (N/A) |
|
Details | ||
| 9/13/2024 | Schrodinger | SDGR | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2024 | Recursion Pharmaceuticals | RXRX | Maintain | Hold (N/A) |
|
Details | ||
| 8/15/2024 | Absci Corp. | ABSI | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2024 | Absci Corp. | ABSI | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2024 | AbCellera Biologics | ABCL | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2024 | Evotec | EVO | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2024 | Twist Bioscience | TWST | Maintain | Buy (N/A) |
|
Details | ||
| 6/13/2024 | Twist Bioscience | TWST | Maintain | Buy (N/A) |
|
Details | ||
| 5/24/2024 | 23andMe Holding | ME | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2024 | Ginkgo Bioworks Holdings Inc | DNA | Maintain | Buy (N/A) |
|
Details | ||
| 1/26/2024 | Recursion Pharmaceuticals | RXRX | New Coverage | Hold (N/A) |
10.23 (3.47) |
-66.08% | Details | |
| 1/26/2024 | Schrodinger | SDGR | New Coverage | Buy (N/A) |
26.86 (14.93) |
-44.42% | Details | |
| 1/9/2024 | Codexis, Inc. | CDXS | Maintain | Hold (N/A) |
|
Details | ||
| 12/12/2023 | Twist Bioscience | TWST | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2023 | Codexis, Inc. | CDXS | Maintain | Hold (N/A) |
|
Details | ||
| 8/23/2023 | PhenomeX Inc | CELL | Downgrade | Hold (Buy) |
0.93 (1.00) |
7.53% | Details | |
| 5/30/2023 | 23andMe Holding | ME | Maintain | Buy (N/A) |
|
Details | ||
| 3/16/2023 | Amyris, Inc. | AMRS | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2023 | AbCellera Biologics | ABCL | New Coverage | Buy (N/A) |
8.43 (5.72) |
-32.15% | Details | |
| 2/22/2023 | OmniAb, Inc. | OABI | New Coverage | Buy (N/A) |
3.86 (2.50) |
-35.23% | Details | |
| 12/13/2022 | Twist Bioscience | TWST | Maintain | Buy (N/A) |
|
Details | ||
| 11/9/2022 | Amyris, Inc. | AMRS | Maintain | Buy (N/A) |
|
Details | ||
| 9/22/2022 | 23ANDME | ME | New Coverage | Buy (N/A) |
2.92 (0.61) |
-79.11% | Details | |
| 8/12/2022 | Absci Corp. | ABSI | Upgrade | Buy (Hold) |
4.79 (5.94) |
24.01% | Details | |
| 7/15/2022 | Codexis, Inc. | CDXS | Maintain | Buy (N/A) |
|
Details | ||
| 6/17/2022 | Codexis, Inc. | CDXS | Maintain | Buy (N/A) |
|
Details | ||
| 6/8/2022 | Twist Bioscience | TWST | Maintain | Buy (Buy) |
|
Details | ||
| 4/5/2022 | Twist Bioscience | TWST | Maintain | Buy (Buy) |
|
Details | ||
| 3/29/2022 | Ginkgo Bioworks Holdings Inc | DNA | Maintain | Buy (Buy) |
|
Details | ||
| 3/24/2022 | Zymergen Inc | ZY | Maintain | Hold (Hold) |
|
Details | ||
| 3/23/2022 | Codex DNA Inc. | DNAY | Maintain | Buy (Buy) |
|
Details | ||
| 3/2/2022 | Zymergen Inc | ZY | New Coverage | Hold (N/A) |
3.80 (2.43) |
-36.05% | Details | |
| 3/2/2022 | Evotec | EVO | New Coverage | Buy (N/A) |
14.48 (2.89) |
-80.04% | Details | |
| 3/2/2022 | Berkeley Lights | BLI | New Coverage | Buy (N/A) |
7.57 (1.20) |
-84.15% | Details | |
| 3/2/2022 | Amyris, Inc. | AMRS | New Coverage | Buy (N/A) |
4.77 (9454.42) |
198105.87% | Details | |
| 3/2/2022 | Twist Bioscience | TWST | New Coverage | Buy (N/A) |
55.50 (72.33) |
30.32% | Details | |
| 3/2/2022 | Codexis, Inc. | CDXS | New Coverage | Buy (N/A) |
19.64 (2.72) |
-86.15% | Details | |
| 3/2/2022 | Ginkgo Bioworks Holdings Inc | DNA | New Coverage | Buy (N/A) |
4.29 (8.73) |
103.5% | Details | |
| 3/2/2022 | Codex DNA Inc. | DNAY | New Coverage | Buy (N/A) |
9.65 (1.30) |
-86.53% | Details | |
| 3/2/2022 | Absci Corp. | ABSI | New Coverage | Hold (N/A) |
9.28 (5.94) |
-35.99% | Details |
